KRAS and colorectal carcinoma: It has been found that ginsenoside Rh3 (GRh3) prevents the entry of Nrf2 into the nucleus, which inhibits SLC7A11, leading to depletion of GSH, which decreases GPX4 activity, ultimately leading to the accumulation of iron, ROS, and malondialdehyde (MDA), and ferroptosis in CRC cells (88).β-elemene, an active substance isolated from turmeric, can inhibit KRAS mutant CRC tumor growth by inducing ferroptosis combination with cetuximab and inhibit tumor migration by modulating EMT.